IL159517A0 - Combinations comprising epothilones and pharmaceutical uses thereof - Google Patents

Combinations comprising epothilones and pharmaceutical uses thereof

Info

Publication number
IL159517A0
IL159517A0 IL15951702A IL15951702A IL159517A0 IL 159517 A0 IL159517 A0 IL 159517A0 IL 15951702 A IL15951702 A IL 15951702A IL 15951702 A IL15951702 A IL 15951702A IL 159517 A0 IL159517 A0 IL 159517A0
Authority
IL
Israel
Prior art keywords
epothilones
combinations
pharmaceutical uses
pharmaceutical
Prior art date
Application number
IL15951702A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/008020 external-priority patent/WO2002074419A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL159517A0 publication Critical patent/IL159517A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15951702A 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof IL159517A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30657101P 2001-07-19 2001-07-19
US30656001P 2001-07-19 2001-07-19
US30655901P 2001-07-19 2001-07-19
PCT/US2002/008020 WO2002074419A1 (en) 2001-03-19 2002-03-13 Filter system

Publications (1)

Publication Number Publication Date
IL159517A0 true IL159517A0 (en) 2004-06-01

Family

ID=27405180

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15951702A IL159517A0 (en) 2001-07-19 2002-07-18 Combinations comprising epothilones and pharmaceutical uses thereof
IL159517A IL159517A (en) 2001-07-19 2003-12-22 Combinations containing vasculostatic compound and the result of apothilone and their uses in the preparation of drugs for the treatment of proliferative diseases and diseases related to uncontrolled angiogenesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159517A IL159517A (en) 2001-07-19 2003-12-22 Combinations containing vasculostatic compound and the result of apothilone and their uses in the preparation of drugs for the treatment of proliferative diseases and diseases related to uncontrolled angiogenesis

Country Status (19)

Country Link
US (3) US20040235796A1 (es)
EP (2) EP2210643A3 (es)
JP (2) JP2005501825A (es)
KR (2) KR20090040925A (es)
CN (2) CN101791308A (es)
AU (2) AU2002328921B2 (es)
BR (1) BR0211271A (es)
CA (1) CA2453108A1 (es)
CO (1) CO5560565A2 (es)
EC (2) ECSP084948A (es)
HU (1) HUP0401153A3 (es)
IL (2) IL159517A0 (es)
MX (1) MXPA04000567A (es)
NO (1) NO20040214L (es)
NZ (2) NZ530572A (es)
PL (1) PL365030A1 (es)
RU (1) RU2375058C2 (es)
TW (1) TWI315982B (es)
WO (1) WO2003007924A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1383490B1 (en) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
KR101153647B1 (ko) 2003-11-18 2012-06-18 노파르티스 아게 Kit 돌연변이형에 대한 저해제
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
RU2445960C2 (ru) 2005-05-02 2012-03-27 Новартис Аг Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
RU2478407C1 (ru) * 2011-09-05 2013-04-10 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Способ комбинированного лечения местно-распространенного рака желудка

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) * 1946-10-22 Method for obtaining hydantoins
US3475486A (en) * 1966-09-12 1969-10-28 Monsanto Co Process for preparing phosphonic acids
NL7304882A (es) 1972-04-10 1973-10-12
CH605550A5 (es) 1972-06-08 1978-09-29 Research Corp
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
AU5953894A (en) 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
PT1186606E (pt) * 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
NZ506389A (en) 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
DK1156823T3 (da) 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
BR0010808A (pt) * 1999-05-21 2002-08-27 Novartis Ag Composições farmacêuticas e usos
WO2001049295A1 (en) * 2000-01-04 2001-07-12 The Regents Of The University Of California Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
ATE295365T1 (de) 2000-02-09 2005-05-15 Novartis Pharma Gmbh Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
EP1383490B1 (en) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof

Also Published As

Publication number Publication date
HUP0401153A3 (en) 2008-01-28
KR20040030808A (ko) 2004-04-09
HUP0401153A2 (hu) 2004-10-28
IL159517A (en) 2012-04-30
CN101791308A (zh) 2010-08-04
TWI315982B (en) 2009-10-21
JP2010159271A (ja) 2010-07-22
WO2003007924A3 (en) 2003-09-25
CN1533293A (zh) 2004-09-29
WO2003007924A2 (en) 2003-01-30
ECSP084948A (es) 2008-08-29
US20090318390A1 (en) 2009-12-24
AU2002328921B2 (en) 2006-11-02
EP1412029A2 (en) 2004-04-28
US8008330B2 (en) 2011-08-30
KR20090040925A (ko) 2009-04-27
JP2005501825A (ja) 2005-01-20
US7612052B2 (en) 2009-11-03
AU2005246964A1 (en) 2006-01-12
RU2375058C2 (ru) 2009-12-10
CN1283248C (zh) 2006-11-08
PL365030A1 (en) 2004-12-27
NZ550174A (en) 2008-04-30
BR0211271A (pt) 2004-08-03
US20040235796A1 (en) 2004-11-25
US20080119529A1 (en) 2008-05-22
MXPA04000567A (es) 2004-04-20
NO20040214L (no) 2004-03-18
EP2210643A2 (en) 2010-07-28
AU2005246964B2 (en) 2008-04-24
CO5560565A2 (es) 2005-09-30
RU2004105144A (ru) 2005-04-20
EP2210643A3 (en) 2010-11-24
ECSP094948A (es) 2009-12-28
CA2453108A1 (en) 2003-01-30
NZ530572A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
IL158523A0 (en) Epothilone derivatives and pharmaceutical compositions containing the same
EP1408978A4 (en) NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
PL366510A1 (en) Pharmaceutical combinations
IL154553A0 (en) Urocortin-iii and uses thereof
HK1069385A1 (en) Heterocyclic compound and medicinal use thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
TWI315982B (en) Combinations comprising epothilones and pharmaceutical uses thereof
AU2003296369A8 (en) Imminoamines and preparation thereof
GB0126889D0 (en) Compounds and their uses
EP1379228A4 (en) (Z) -STYRYLBENZYLSULPONES AND THEIR PHARMACEUTICAL APPLICATIONS
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
EP1408985A4 (en) NEW PYRIDOPYRIMIDONE AND ITS USES
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
GB0129872D0 (en) Novel pharmaceutical
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
EP1367123A4 (en) NEUROTONIN AND ITS USE
GB0128138D0 (en) Pharmaceutical use
GB0102447D0 (en) Protein variants and uses thereof
GB0129876D0 (en) Novel pharmaceutical
GB0130509D0 (en) Novel pharmaceutical